In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.
about
Molecular Selection, Modification and Development of Therapeutic Oligonucleotide AptamersIn vitro selection using modified or unnatural nucleotidesRacemic DNA crystallographyPegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.Vascular endothelial growth factor as an anti-angiogenic target for cancer therapyShort bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEXNucleic acid aptamers in cancer medicine.Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats.Spiegelmers: biostable aptamers.Deconvolution of a complex target using DNA aptamers.Enhanced functional potential of nucleic acid aptamer libraries patterned to increase secondary structureStrategies for the discovery of therapeutic aptamers.Crosstalk between Gut Microbiota and Dietary Lipids Aggravates WAT Inflammation through TLR Signaling.An L-RNA-based aquaretic agent that inhibits vasopressin in vivo.In vivo imaging with oligonucleotides for diagnosis and drug development.Nucleic acid aptamers as tools and drugs: recent developments.Aptamers as a novel tool for diagnostics and therapy.Aptamers: new arrows to target dendritic cells.Ligand-dependent exponential amplification of a self-replicating L-RNA enzyme.A mixed mirror-image DNA/RNA aptamer inhibits glucagon and acutely improves glucose tolerance in models of type 1 and type 2 diabetes.Binding of a structured D-RNA molecule by an L-RNA aptamer.Characterization of RNA aptamers that disrupt the RUNX1-CBFbeta/DNA complex.Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer.Exploring the role of chirality in nucleic acid recognition.Chimeric aptamers in cancer cell-targeted drug deliveryCharacterisation of aptamers for therapeutic studies.Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?Anti-Transcription Factor RNA Aptamers as Potential Therapeutics.Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonucleotide.Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo.A DNA Spiegelmer to staphylococcal enterotoxin B.Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.Internal 32P-labeling of L-deoxyoligonucleotidesBottom-up Assembly of RNA Arrays and Superstructures as Potential Parts in Nanotechnology.Chemical Modifications of Nucleic Acid Aptamers for Therapeutic Purposes.Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice.An L-DNA G-quadruplex: application for peroxidase DNAzyme.Oligonucleotide therapies for disorders of the nervous system.DNA vs. Mirror-Image DNA: A Universal Approach to Tune the Absolute Configuration in DNA-Based Asymmetric CatalysisA mirror-image tetramolecular DNA quadruplex
P2860
Q26765458-30CD01D7-C62A-4F5C-89AB-7A9F455C39CCQ26864079-F25DD833-0FEF-4EB4-8A7E-7EAEAAD1E667Q27695944-6302197A-2563-4DC8-837C-3CDBC236042CQ30440705-05C3DE3F-E846-4FA5-8ABA-F327F751288CQ30455612-C1C96D26-D1C1-4F07-9D7A-EDD5A562B411Q30823550-0F15C062-D827-4793-8771-EB50A48A865FQ30854890-5B2EF7BF-C5CB-4440-B4D0-3768C1DE7381Q30968739-55A14F91-9C82-4B5F-84E6-F32535F6B6F8Q31005222-A4613BE0-3792-4357-A42E-7F5462D1683BQ33221136-13DF84C6-8811-4D58-BBFB-36A18FBCC566Q33610517-DE70A6CB-7FF7-4F90-A4F5-AAD524F17321Q33831862-D40C57DC-9099-42C8-B5B2-C58BC6547F2BQ34491604-D8CE71A2-824C-48C4-A9EA-22001FA249CEQ34597041-1836351F-313A-4040-87A9-8567C829611DQ35127223-A59C3D32-C3B9-4BD0-AC6D-120D1FEC444EQ35549348-2B6773DA-6005-4C25-9335-5260A9A0C073Q35552275-9108D742-0228-40FC-9804-BC3BA14BC85CQ35624065-5694A8A9-0F5E-4429-93AA-966F8866B153Q35975936-293486B5-128E-448F-9CA3-00D32B8E5B98Q37175145-2AE5CF01-31E0-435B-BE99-55E14AC1536DQ37245220-BB165B57-37D5-4EF6-B23B-AD268A123201Q37421114-D10E7A8B-2430-4470-9742-6F021F857016Q37513215-1A1E0690-507B-4791-872F-AA06DDAE95CCQ37853120-4C0982BF-E977-41EC-8120-8554776D4602Q37939984-EE2F9CB2-8067-44EA-BE5E-3462CA674BE0Q38089865-9811263E-DCE5-48E9-A18D-98AA6C54E4BEQ38166624-9A4AA149-4D06-4DAB-B7B2-46976FDB55A0Q38295683-140E0A52-8496-420B-AE14-AD319F9654B9Q38313986-50572EFA-2291-4D38-AD23-1D4456FE2500Q38339945-B0E4CF5D-05B0-4566-9171-63F4935483EDQ38353738-27B79386-F760-4D60-AE7D-47E1ADE9BA22Q39678049-5550D8E8-7A2D-43FD-A08D-85121FA0454AQ39744523-F0B0A9F6-274C-4592-998D-6668EEAF2C8EQ41476047-4922F4A6-5857-49FB-A9A7-9129268290CEQ41573492-55F9D149-A63E-4F93-8A42-212662E275DDQ41788971-8EB87C58-3F68-4F67-AE30-EB7AAF2ED735Q46963016-2876A8C0-31BA-4FA8-9C54-22BAB88037C2Q48288187-A5257CD8-B2FF-4D2A-B6B9-2747C809C2CBQ56789047-7D58AA41-4FD3-4BF7-BD58-79AE6A4FF87DQ57744043-500CA3CA-52F7-4543-BE11-2EBE1F276FCF
P2860
In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vivo properties of an anti- ...... ed therapeutic substance class
@nl
In vivo properties of an anti- ...... d therapeutic substance class.
@ast
In vivo properties of an anti- ...... d therapeutic substance class.
@en
In vivo properties of an anti- ...... d therapeutic substance class.
@en-gb
type
label
In vivo properties of an anti- ...... ed therapeutic substance class
@nl
In vivo properties of an anti- ...... d therapeutic substance class.
@ast
In vivo properties of an anti- ...... d therapeutic substance class.
@en
In vivo properties of an anti- ...... d therapeutic substance class.
@en-gb
prefLabel
In vivo properties of an anti- ...... ed therapeutic substance class
@nl
In vivo properties of an anti- ...... d therapeutic substance class.
@ast
In vivo properties of an anti- ...... d therapeutic substance class.
@en
In vivo properties of an anti- ...... d therapeutic substance class.
@en-gb
P2093
P2860
P356
P1476
In vivo properties of an anti- ...... d therapeutic substance class.
@en
P2093
Bernd Eschgfäller
Britta Wlotzka
Christine Kaduk
Frank Kleinjung
Holger Hess-Stumpp
Jens Burmeister
Peter Muhn
Susanne Leva
Sven Klussmann
P2860
P304
P356
10.1073/PNAS.132067399
P407
P577
2002-06-17T00:00:00Z